Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

• Conditions: Biomarkers for Efficacy and Toxicity; Drug Resistance to Famitinib and Camrelizumab

• Registration Number: NCT03919539
• Lead Sponsor: Peking University People's Hospital

Brief Summary

hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma. From our previous trials, we identify geno sequencing related to beta-catenin pathways might have some relationship with osteosaroma primary or secondary drug resistance. Thus in this trial we try to further explore the drug resistance mechanism for advaced osteosarcoma second resistance to the combination therapy of Famitinib and Camrelizumab.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-04-01
• Study First Submitted QC: 2019-04-15
• Study First Posted: 2019-04-18
• Study Start: 2019-12-01
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-04
• Last Update Posted: 2020-02-06
• Primary Completion: 2021-06-01
• Study Completion: 2021-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
5hmc expression rate	24 months

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, Beijing, China